Tigecycline
Generic name
Tigecycline
Brand name
ATC Code
J01AA12
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Infections of the skin and soft tissues and intra-abdominal infections |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
(Irreversible) tooth discoloration in children, tooth development disorder.
The side effects in children match the side-effects in adults.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Use in children < 8 years of age, due to risk of damage to growing bone and dental tissue and irreversible discoloration (yellow/gray/brown) of teeth
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Nausea and vomiting are very commonly occurring side effects in children and adolescents. Special attention should be paid to possible dehydration. Tigecycline should be administered in children preferably during an infusion period of 60 minutes.
Permanent discoloration of developing teeth: Hypoplasia of tooth enamel and permanent discoloration (yellow-gray-brown) of teeth have been reported with the use of tetracyclines during the second half of pregnancy or in children up to 8 years of age. This side effect is more common with long-term use of tetracyclines, but has also been reported after repeated short-term use.
In patients (including children) with severely reduced hepatic function (Child-Pugh class C), the Tygacil dose should be reduced by 50%.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
TETRACYCLINES
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Tetracyclines | ||
|---|---|---|
| J01AA02 | ||
| J01AA08 | ||
| J01AA07 | ||
Reference
- Pfizer Limited, SmPC Tygacil (EU/1/06/336/001) 20-04-2011, www.cbg-meb.nl
Changes
Therapeutic Drug Monitoring
Overdose
